Posted On: 01/22/2016 7:54:27 AM
Post# of 63824
$CYDY sheet coming up later today.
CytoDyn Inc., a biotechnology company, develops therapeutic monoclonal antibodies to address unmet medical needs in the areas of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome. Its lead product candidate is PRO 140 antibody, which is in Phase-III clinical trials and belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The company also develops Cytolin, a humanized monoclonal antibody for the treatment of HIV infection; and CytoFeline, a felinized-monoclonal antibody for the treatment of feline immunodeficiency virus. CytoDyn Inc. is based in Vancouver, Washington.
CytoDyn Inc., a biotechnology company, develops therapeutic monoclonal antibodies to address unmet medical needs in the areas of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome. Its lead product candidate is PRO 140 antibody, which is in Phase-III clinical trials and belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The company also develops Cytolin, a humanized monoclonal antibody for the treatment of HIV infection; and CytoFeline, a felinized-monoclonal antibody for the treatment of feline immunodeficiency virus. CytoDyn Inc. is based in Vancouver, Washington.
(0)
(0)
